News | September 23, 2024
DevCo completes strategic capital raise for investment in Medix Biochemica
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
Majority of organizations are looking to increase investments in public and hybrid cloud
Report highlights significant improvements in adolescent well-being in India
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Merck has opened its newly expanded Life Science distribution center in Schnelldorf, Germany
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
Subscribe To Our Newsletter & Stay Updated
